Abstract
Mesenchymal stem cells (MSCs) have been intensively studied and applied in regenerative medicine and tissue engineering. Recently, their immune modulation functions make them as attractive potential approaches for autoimmune disease treatment. Systemic lupus erythematosus (SLE) is one type of chronic autoimmune diseases with multi-organ damaged by the immune system. Although current available treatments are effective for some patients, others are refractory for these therapies. The immuno-modulatory and regenerative characteristics of MSCs make them as one promising candidate for treating SLE. Thus, we would discuss their immune modulation effects, pre-clinical and clinical applications, and the potentials for immune tolerance re-establishment in SLE here.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- BAFF:
-
B cell activating factor
- BM:
-
bone marrow
- Breg:
-
regulatory B cell
- CCL2:
-
C-C motif chemokine ligand 2
- HSCs:
-
hematopoietic stem cells
- IDO:
-
indoleamine 2,3-dioxygenase
- IFN-γ:
-
interferon-gamma
- IL:
-
interleukin
- iNOS:
-
inducible nitric oxide synthase
- MSCs:
-
mesenchymal stem cells
- OAZ:
-
olfactory 1/early B cell factor-associated zinc-finger protein
- PD:
-
programmed death
- PGE2:
-
prostaglandin E2
- SLE:
-
systemic lupus erythematosus
- Tfh:
-
follicular helper cell
- TGF-β:
-
transforming growth factor beta
- Th:
-
T helper cells
- TNF-α:
-
tumor necrosis factor alpha
- Treg:
-
regulatory T cells
- UC:
-
umbilical cord
References
Acar M et al (2015) Deep imaging of bone marrow shows non-dividing stem cells are mainly perisinusoidal. Nature 526(7571):126–130. https://doi.org/10.1038/nature15250
Akiyama K et al (2012) Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell 10(5):544–555. https://doi.org/10.1016/j.stem.2012.03.007
Ankrum JA et al (2014) Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol 32(3):252–260. https://doi.org/10.1038/nbt.2816
Banchereau R et al (2017) Understanding human autoimmunity and autoinflammation through transcriptomics. Annu Rev Immunol 35:337–370. https://doi.org/10.1146/annurev-immunol-051116-052225
Bernardo ME, Fibbe WE (2013) Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell 13(4):392–402. https://doi.org/10.1016/j.stem.2013.09.006
Bernatsky S et al (2006) Mortality in systemic lupus erythematosus. Arthritis Rheum 54(8):2550–2557. https://doi.org/10.1002/art.21955
Bianco P et al (2008) Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell 2(4):313–319. https://doi.org/10.1016/j.stem.2008.03.002
Carrion F et al (2010) Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients. Lupus 19(3):317–322. https://doi.org/10.1177/0961203309348983
Chan MC et al (2016) Human mesenchymal stromal cells reduce influenza a H5N1-associated acute lung injury in vitro and in vivo. Proc Natl Acad Sci U S A 113(13):3621–3626. https://doi.org/10.1073/pnas.1601911113
Chang JW et al (2011) Therapeutic effects of umbilical cord blood-derived mesenchymal stem cell transplantation in experimental lupus nephritis. Cell Transplant 20(2):245–257. https://doi.org/10.3727/096368910X520056
Che N et al (2014) Impaired B cell inhibition by lupus bone marrow mesenchymal stem cells is caused by reduced CCL2 expression. J Immunol 193(10):5306–5314. https://doi.org/10.4049/jimmunol.1400036
Choi EW et al (2012) Reversal of serologic, immunologic, and histologic dysfunction in mice with systemic lupus erythematosus by long-term serial adipose tissue-derived mesenchymal stem cell transplantation. Arthritis Rheum 64(1):243–253. https://doi.org/10.1002/art.33313
Choi EW et al (2015) Transplantation of adipose tissue-derived mesenchymal stem cells prevents the development of lupus dermatitis. Stem Cells Dev 24(17):2041–2051. https://doi.org/10.1089/scd.2015.0021
Contreras-Kallens P et al (2017) Mesenchymal stem cells and their immunosuppressive role in transplantation tolerance. Ann N Y Acad Sci. https://doi.org/10.1111/nyas.13364
Deng W et al (2015) Mesenchymal stem cells promote CD206 expression and phagocytic activity of macrophages through IL-6 in systemic lupus erythematosus. Clin Immunol 161(2):209–216. https://doi.org/10.1016/j.clim.2015.07.011
Deng D et al (2017) A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis. Ann Rheum Dis 76(8):1436–1439. https://doi.org/10.1136/annrheumdis-2017-211073
Dominici M et al (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4):315–317. https://doi.org/10.1080/14653240600855905
El Agha E et al (2017) Mesenchymal stem cells in fibrotic disease. Cell Stem Cell 21(2):166–177. https://doi.org/10.1016/j.stem.2017.07.011
Feng X et al (2014) Restored immunosuppressive effect of mesenchymal stem cells on B cells after olfactory 1/early B cell factor-associated zinc-finger protein down-regulation in patients with systemic lupus erythematosus. Arthritis Rheumatol 66(12):3413–3423. https://doi.org/10.1002/art.38879
Gao L et al (2016) Phase II multicenter, randomized, double-blind controlled study of efficacy and safety of umbilical cord-derived mesenchymal stromal cells in the prophylaxis of chronic graft-versus-host disease after HLA-Haploidentical stem-cell transplantation. J Clin Oncol 34(24):2843–2850. https://doi.org/10.1200/JCO.2015.65.3642
Gao L et al (2017) Bone marrow-derived mesenchymal stem cells from patients with systemic lupus erythematosus have a senescence-associated secretory phenotype mediated by a mitochondrial antiviral signaling protein-interferon-beta feedback loop. Arthritis Rheumatol 69(8):1623–1635. https://doi.org/10.1002/art.40142
Gu Z et al (2010) Transplantation of umbilical cord mesenchymal stem cells alleviates lupus nephritis in MRL/lpr mice. Lupus 19(13):1502–1514. https://doi.org/10.1177/0961203310373782
Gu F et al (2014a) Allogeneic mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy. Clin Rheumatol 33(11):1611–1619. https://doi.org/10.1007/s10067-014-2754-4
Gu Z et al (2014b) Wnt/beta-catenin signaling mediates the senescence of bone marrow-mesenchymal stem cells from systemic lupus erythematosus patients through the p53/p21 pathway. Mol Cell Biochem 387(1–2):27–37. https://doi.org/10.1007/s11010-013-1866-5
Hahn BH (2013) Belimumab for systemic lupus erythematosus. N Engl J Med 368(16):1528–1535. https://doi.org/10.1056/NEJMct1207259
He X et al (2016) Suppression of interleukin 17 contributes to the immunomodulatory effects of adipose-derived stem cells in a murine model of systemic lupus erythematosus. Immunol Res 64(5–6):1157–1167. https://doi.org/10.1007/s12026-016-8866-y
Heldring N et al (2015) Therapeutic potential of multipotent mesenchymal stromal cells and their extracellular vesicles. Hum Gene Ther 26(8):506–517. https://doi.org/10.1089/hum.2015.072
Jang E et al (2016) Infusion of human bone marrow-derived mesenchymal stem cells alleviates autoimmune nephritis in a lupus model by suppressing follicular helper T-cell development. Cell Transplant 25(1):1–15. https://doi.org/10.3727/096368915X688173
Ji S et al (2012) Mesenchymal stem cell transplantation inhibits abnormal activation of Akt/GSK3beta signaling pathway in T cells from systemic lupus erythematosus mice. Cell Physiol Biochem 29(5–6):705–712. https://doi.org/10.1159/000178590
Joseph CG et al (2014) Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 343(6167):152–157. https://doi.org/10.1126/science.1246886
Kamal A, Khamashta M (2014) The efficacy of novel B cell biologics as the future of SLE treatment: a review. Autoimmun Rev 13(11):1094–1101. https://doi.org/10.1016/j.autrev.2014.08.020
Karp JM, Leng Teo GS (2009) Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 4(3):206–216. https://doi.org/10.1016/j.stem.2009.02.001
Keating A (2012) Mesenchymal stromal cells: new directions. Cell Stem Cell 10(6):709–716. https://doi.org/10.1016/j.stem.2012.05.015
Ko JH et al (2016) Mesenchymal stem/stromal cells precondition lung monocytes/macrophages to produce tolerance against Allo- and autoimmunity in the eye. Proc Natl Acad Sci U S A 113(1):158–163. https://doi.org/10.1073/pnas.1522905113
Le Blanc K et al (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363(9419):1439–1441. https://doi.org/10.1016/S0140-6736(04)16104-7
Le Blanc K et al (2008) Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371(9624):1579–1586. https://doi.org/10.1016/S0140-6736(08)60690-X
Lee YH et al (2016) Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus 25(7):727–734. https://doi.org/10.1177/0961203315627202
Li X et al (2012) Enhanced apoptosis and senescence of bone-marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Stem Cells Dev 21(13):2387–2394. https://doi.org/10.1089/scd.2011.0447
Li X et al (2013) Mesenchymal SCT ameliorates refractory cytopenia in patients with systemic lupus erythematosus. Bone Marrow Transplant 48(4):544–550. https://doi.org/10.1038/bmt.2012.184
Liang J et al (2010) Mesenchymal stem cell transplantation for diffuse alveolar hemorrhage in SLE. Nat Rev Rheumatol 6(8):486–489. https://doi.org/10.1038/nrrheum.2010.80
Liao J et al (2015) Cell-based therapies for systemic lupus erythematosus. Autoimmun Rev 14(1):43–48. https://doi.org/10.1016/j.autrev.2014.10.001
Lisnevskaia L et al (2014) Systemic lupus erythematosus. Lancet 384(9957):1878–1888. https://doi.org/10.1016/S0140-6736(14)60128-8
Lv FJ et al (2014) Concise review: the surface markers and identity of human mesenchymal stem cells. Stem Cells 32(6):1408–1419. https://doi.org/10.1002/stem.1681
Ma X et al (2013) Allogenic mesenchymal stem cell transplantation ameliorates nephritis in lupus mice via inhibition of B-cell activation. Cell Transplant 22(12):2279–2290. https://doi.org/10.3727/096368912X658692
Mo M et al (2016) Mesenchymal stem cell subpopulations: phenotype, property and therapeutic potential. Cell Mol Life Sci 73(17):3311–3321. https://doi.org/10.1007/s00018-016-2229-7
Murphy G et al (2013) Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment. Lancet 382(9894):809–818. https://doi.org/10.1016/S0140-6736(13)60889-2
Nie Y et al (2010) Defective phenotype of mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus 19(7):850–859. https://doi.org/10.1177/0961203309361482
Park MJ et al (2015) Adipose tissue-derived mesenchymal stem cells induce expansion of interleukin-10-producing regulatory B cells and ameliorate autoimmunity in a murine model of systemic lupus erythematosus. Cell Transplant 24(11):2367–2377. https://doi.org/10.3727/096368914X685645
Phillips CD et al (2017) Purified umbilical cord derived mesenchymal stem cell treatment in a case of systemic lupus erythematosus. Clin Transl Med 6(1):31. https://doi.org/10.1186/s40169-017-0161-6
Phinney DG et al (2015) Mesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuttle microRNAs. Nat Commun 6:8472. https://doi.org/10.1038/ncomms9472
Pittenger MF et al (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284(5411):143–147
Polchert D et al (2008) IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 38(6):1745–1755. https://doi.org/10.1002/eji.200738129
Rasmusson I et al (2007) Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand J Immunol 65(4):336–343. https://doi.org/10.1111/j.1365-3083.2007.01905.x
Reinisch A et al (2015) Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation. Blood 125(2):249–260. https://doi.org/10.1182/blood-2014-04-572255
Rosado MM et al (2015) Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells. Stem Cells Dev 24(1):93–103. https://doi.org/10.1089/scd.2014.0155
Schena F et al (2010) Interferon-gamma-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. Arthritis Rheum 62(9):2776–2786. https://doi.org/10.1002/art.27560
Shi D et al (2012) Allogeneic transplantation of umbilical cord-derived mesenchymal stem cells for diffuse alveolar hemorrhage in systemic lupus erythematosus. Clin Rheumatol 31(5):841–846. https://doi.org/10.1007/s10067-012-1943-2
Shi D et al (2014) High level of reactive oxygen species impaired mesenchymal stem cell migration via overpolymerization of F-actin cytoskeleton in systemic lupus erythematosus. Pathol Biol (Paris) 62(6):382–390. https://doi.org/10.1016/j.patbio.2014.07.009
Sun LY et al (2007) Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus 16(2):121–128. https://doi.org/10.1177/0961203306075793
Sun L et al (2009) Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 27(6):1421–1432. https://doi.org/10.1002/stem.68
Sun L et al (2010) Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum 62(8):2467–2475. https://doi.org/10.1002/art.27548
Thiel A et al (2015) Human embryonic stem cell-derived mesenchymal cells preserve kidney function and extend lifespan in NZB/W F1 mouse model of lupus nephritis. Sci Rep 5:17685. https://doi.org/10.1038/srep17685
Trial J et al (2016) Mesenchymal stem cell-derived inflammatory fibroblasts mediate interstitial fibrosis in the aging heart. J Mol Cell Cardiol 91:28–34. https://doi.org/10.1016/j.yjmcc.2015.12.017
Tsokos GC (2011) Systemic lupus erythematosus. N Engl J Med 365(22):2110–2121. https://doi.org/10.1056/NEJMra1100359
Tsokos GC et al (2016) New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol 12(12):716–730. https://doi.org/10.1038/nrrheum.2016.186
Tyndall A (2009) Cellular therapy of systemic lupus erythematosus. Lupus 18(5):387–393. https://doi.org/10.1177/0961203308100385
Tyndall A (2014) Mesenchymal stem cell treatments in rheumatology: a glass half full? Nat Rev Rheumatol 10(2):117–124. https://doi.org/10.1038/nrrheum.2013.166
Uccelli A et al (2008) Mesenchymal stem cells in health and disease. Nat Rev Immunol 8(9):726–736. https://doi.org/10.1038/nri2395
van Kempen TS et al (2015) Perception of self: distinguishing autoimmunity from autoinflammation. Nat Rev Rheumatol 11(8):483–492. https://doi.org/10.1038/nrrheum.2015.60
Wang D et al (2013) Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. Cell Transplant 22(12):2267–2277. https://doi.org/10.3727/096368911X582769
Wang D et al (2014a) A CD8 T cell/indoleamine 2,3-dioxygenase axis is required for mesenchymal stem cell suppression of human systemic lupus erythematosus. Arthritis Rheumatol 66(8):2234–2245. https://doi.org/10.1002/art.38674
Wang D et al (2014b) Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. Arthritis Res Ther 16(2):R79. https://doi.org/10.1186/ar4520
Wang Y et al (2014c) Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol 15(11):1009–1016. https://doi.org/10.1038/ni.3002
Wang Q et al (2015) Combined transplantation of autologous hematopoietic stem cells and allogenic mesenchymal stem cells increases T regulatory cells in systemic lupus erythematosus with refractory lupus nephritis and leukopenia. Lupus 24(11):1221–1226. https://doi.org/10.1177/0961203315583541
Wang D et al (2017a) The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus. Cell Mol Immunol 14(5):423–431. https://doi.org/10.1038/cmi.2015.89
Wang D et al (2017b) Long-term safety of umbilical cord mesenchymal stem cells transplantation for systemic lupus erythematosus: a 6-year follow-up study. Clin Exp Med 17(3):333–340. https://doi.org/10.1007/s10238-016-0427-0
Wang D et al (2017c) Serum IFN-gamma predicts the therapeutic effect of mesenchymal stem cells transplantation in systemic lupus erythematosus patients. Stem Cells Transl Med. https://doi.org/10.1002/sctm.17-0002
Xiong W, Lahita RG (2014) Pragmatic approaches to therapy for systemic lupus erythematosus. Nat Rev Rheumatol 10(2):97–107. https://doi.org/10.1038/nrrheum.2013.157
Zhang Y et al (2014) Transplantation of umbilical cord mesenchymal stem cells alleviates pneumonitis of MRL/lpr mice. J Thorac Dis 6(2):109–117. https://doi.org/10.3978/j.issn.2072-1439.2013.12.48
Zhang Z et al (2017) Human umbilical cord mesenchymal stem cells inhibit T follicular helper cell expansion through the activation of iNOS in lupus-prone B6.MRL-Faslpr mice. Cell Transplant 26(6):1031–1042. https://doi.org/10.3727/096368917X694660
Zhou K et al (2008) Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cell Mol Immunol 5(6):417–424. https://doi.org/10.1038/cmi.2008.52
Acknowledgements
This work was supported by Natural Science Foundation of SZU (2017083), Natural Science Foundation of Shenzhen (JCYJ20170302152735071) and Medical Foundation of Guangdong (A2018308).
Conflict of Interest
The authors declare no commercial or financial conflict of interest.
Ethical Approval
The authors declare that this article does not contain any studies with human participants or animals.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Xu, J. (2018). Therapeutic Applications of Mesenchymal Stem Cells for Systemic Lupus Erythematosus. In: Turksen, K. (eds) Cell Biology and Translational Medicine, Volume 2. Advances in Experimental Medicine and Biology(), vol 1089. Springer, Cham. https://doi.org/10.1007/5584_2018_212
Download citation
DOI: https://doi.org/10.1007/5584_2018_212
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-04169-4
Online ISBN: 978-3-030-04170-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)